Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Jaguar Animal Health ( (JAGX) ) is now available.
On August 19, 2025, Jaguar Health held its Annual Meeting of Stockholders, where seven proposals were approved, including the election of directors and amendments to stock plans. The company also announced promising results from trials of crofelemer for gastrointestinal conditions and outlined plans for regulatory pathways and business development partnerships, potentially impacting its market strategy and stakeholder interests.
The most recent analyst rating on (JAGX) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Jaguar Animal Health stock, see the JAGX Stock Forecast page.
Spark’s Take on JAGX Stock
According to Spark, TipRanks’ AI Analyst, JAGX is a Neutral.
Jaguar Animal Health’s overall stock score is primarily impacted by its weak financial performance, characterized by high leverage and consistent net losses. While there are some positive developments in clinical trials and corporate actions, these are not sufficient to offset the financial challenges. The technical analysis also indicates bearish momentum, further contributing to the low score.
To see Spark’s full report on JAGX stock, click here.
More about Jaguar Animal Health
Jaguar Health, Inc. is a commercial stage pharmaceuticals company that develops novel proprietary prescription medicines derived from plants in rainforest areas. The company focuses on treating gastrointestinal distress, particularly overactive bowel conditions, in both humans and animals. Its subsidiary, Napo Pharmaceuticals, specializes in human prescription pharmaceuticals for neglected gastrointestinal symptoms, while Napo Therapeutics aims to expand access to crofelemer in Europe for orphan diseases. Additionally, Jaguar is involved in mental health medicine development through its joint venture, Magdalena Biosciences.
Average Trading Volume: 98,349
Technical Sentiment Signal: Sell
Current Market Cap: $4.02M
For detailed information about JAGX stock, go to TipRanks’ Stock Analysis page.